Selvas Healthcare Inc

Selvas Healthcare Inc maintains a strong liquidity position, with a current ratio of 9.15 and cash and equivalents amounting to 9,381,594,510 KRW, indicating robust short-term financial flexibility. The company's debt-to-equity ratio is 0.02, reflecting a conservative capital structure with minimal leverage. Free cash flow of 3,701,525,280 KRW supports operational flexibility and potential reinvestment. Profitability metrics show a return on equity (ROE) of 5.47% and a return on assets (ROA) of 4.92%, which are in line with the industry's preferred metrics for capital efficiency. Despite an operating loss of 161,563,030 KRW, the company reported a net income of 3,889,027,540 KRW, suggesting effective cost management and non-operating income contributions. The company's revenue is concentrated in disclosed segments, with no specific geographic breakdown provided in the input data. However, the company's primary operations are based in South Korea, and its exposure to international markets is not quantified in the available data. Outlook for the current fiscal year indicates a stable revenue trajectory, with no significant growth or contraction expected. The company's capital expenditure of -1,101,695,260 KRW suggests a focus on cost optimization rather than expansion. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. Recent financial filings and transcripts do not highlight any material events or strategic shifts. The company's last actual EPS was reported at -231.11 KRW, indicating a negative earnings performance in the most recent period.